Zevra Therapeutics CEO resigns; Q1 net loss widens to $11.8M, revenue $2.9M

ZEVRA THERAPEUTICS, INC.

CEO Richard W. Pascoe resigns effective June 1, 2023; Chief Development Officer Christal Mickle appointed interim CEO.
Q1 net loss of $11.8M ($0.34 per share) vs $1.9M loss a year ago; revenue fell to $2.9M from $4.0M.
Cash and investments $95.3M; expects operating runway into 2026, funding arimoclomol NDA resubmission and KP1077 program.
Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023; KP1077 Phase 2 IH interim data expected Q3 2023.
Share repurchases of 665,739 shares for ~$3.4M during Q1; $39.1M remaining under program.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard W. Pascoe

Chief Executive Officer

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-06-01
Successor: Christal M. M. Mickle
Filed: May 15, 2023, 7:59 PM ET

As previously reported, Richard W. Pascoe resigned as Zevra’s Chief Executive Officer, effective as of the Effective Date.

Appointed (interim)

Christal M. M. Mickle

interim President and Chief Executive Officer

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-06-01
Filed: May 15, 2023, 7:59 PM ET

On May 13, 2023, Zevra’s Board of Directors (the “Board”) appointed Christal M.M. Mickle, Zevra’s Chief Development Officer, as Zevra’s interim President and Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: EPS ($0.34) per basic and diluted share.

Period: first quarter ended March 31, 2023
EPS: ($0.34) per basic and diluted share
Result: reported results

Exact text from the filing

Net revenue for Q1 2023 was $2.9 million compared to Q1 2022 net revenue of $4.0 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: EPS ($0.34) per basic and diluted share.

Period: first quarter ended March 31, 2023
EPS: ($0.34) per basic and diluted share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for Q1 2023 was ($11.8) million, or ($0.34) per basic and diluted share

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard W. Pascoe resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

As previously reported, Richard W. Pascoe resigned as Zevra’s Chief Executive Officer, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christal M. M. Mickle was appointed as interim President and Chief Executive Officer at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: interim President and Chief Executive Officer

Exact text from the filing

On May 13, 2023, Zevra’s Board of Directors (the “Board”) appointed Christal M.M. Mickle, Zevra’s Chief Development Officer, as Zevra’s interim President and Chief Executive Officer

View on SEC.gov

Browse all earnings releases →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-014570

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.